论文部分内容阅读
历时4年的恩度联合达卡巴嗪与安慰剂联合达卡巴嗪一线治疗进展期黑色素瘤的多中心、双盲、随机对照2期临床研究已经完成,我国成为了全球首个完成恩度联合达卡巴嗪一线治疗进展期黑色素瘤2期临床研究的国家,并且诞生了晚期恶性黑色素瘤中国方案。
A 4-year multicenter, double-blind, randomized, controlled double-phase clinical trial of entecavir combined with dacarbazine and placebo in the first-line treatment of advanced melanoma has been completed and our country became the first in the world to complete Ende United Carbazepine first-line treatment of advanced melanoma phase 2 clinical study of the country, and the birth of the Chinese program of advanced malignant melanoma.